SEARCH:   Advanced

Blood, 15 November 2005, Vol. 106, No. 10, pp. 3658-3665. Prepublished online as a Blood First Edition Paper on August 2, 2005; DOI 10.1182/blood-2005-03-1323. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-03-1323v1 106/10/3658    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gale, R. E. Articles by Linch, D. C. Search for Related Content PubMed PubMed Citation Articles by Gale, R. E. Articles by Linch, D. C. Related Collections Neoplasia Transplantation Oncogenes and Tumor Suppressors Clinical Trials and Observations Related Article in Blood Online Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials Rosemary E. Gale, Robert Hills, Panagiotis D. Kottaridis, Sivatharsini Srirangan, Keith Wheatley, Alan K. Burnett, and David C. Linch From the Department of Haematology, Royal Free and University College Medical School, London, United Kingdom; Clinical Trials Unit, University Birmingham, Birmingham, United Kingdom; Department of Haematology, University of Wales, Cardiff, Wales, on behalf of the National Cancer Research Institute (NCRI) Adult Leukaemia Working Party, United Kingdom. Fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) are powerful adverse prognostic indicators for relapse in acute myeloid leukemia (AML) but the most efficacious therapy for FLT3/ITD+ patients is currently unknown. We evaluated outcome according to FLT3/ITD status in 1135 adult patients treated according to United Kingdom Medical Research Council (UK MRC) AML protocols: 141 received an autograft, and 170 received a matched sibling allograft in first complete remission (CR). An FLT3/ITD was detected in 25% of patients and was an independent predictor for relapse (P < .001). It remained prognostic for increased relapse in patients who received a transplant (odds ratio [OR] = 1.91; 95% confidence intervals [CIs] = 1.13-3.21; P = .02), with no evidence of a difference in effect between patients who received an autograft (OR = 2.39; CIs = 1.24-4.62) and patients who received an allograft (OR = 1.31; CIs = 0.56-3.06) (test for interaction, P = .3) or between patients who did or did not receive a transplant (P = .4). These results were confirmed in an analysis of 186 patients randomized to receive or not receive an autograft in first CR and in a donor-versus–no donor analysis of 683 patients to assess the role of allograft (for latter, FLT3/ITD- OR = 0.70, CIs = 0.53-0.92; FLT3/ITD+ OR = 0.59, CIs = 0.40-0.87; test for interaction, P = .5). These results suggest that at present there is no strong evidence that FLT3 status should influence the decision to proceed to transplantation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: More flitting about FLT3 Mark R. Litzow Blood 2005 106: 3331-3332. [Full Text] [PDF] Related Letter in Blood Online: Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML Soheil Meshinchi, Robert J. Arceci, Jean E. Sanders, Franklin O. Smith, William B. Woods, Jerald P. Radich, Todd A. Alonzo, Rosemary E. Gale, Robert Hills, Keith Wheatley, Alan K. Burnett, and David C. Linch Blood 2006 108: 400-401. [Full Text] [PDF] This article has been cited by other articles: R. F. Schlenk, K. Dohner, J. Krauter, S. Frohling, A. Corbacioglu, L. Bullinger, M. Habdank, D. Spath, M. Morgan, A. Benner, et al. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia N. Engl. J. Med., May 1, 2008; 358(18): 1909 - 1918. [Abstract] [Full Text] [PDF] R. E. Gale, C. Green, C. Allen, A. J. Mead, A. K. Burnett, R. K. Hills, D. C. Linch, and on behalf of the Medical Research Council Adult Le The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Blood, March 1, 2008; 111(5): 2776 - 2784. [Abstract] [Full Text] [PDF] A. J. Mead, D. C. Linch, R. K. Hills, K. Wheatley, A. K. Burnett, and R. E. Gale FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia Blood, August 15, 2007; 110(4): 1262 - 1270. [Abstract] [Full Text] [PDF] G. Marcucci, K. Maharry, S. P. Whitman, T. Vukosavljevic, P. Paschka, C. Langer, K. Mrozek, C. D. Baldus, A. J. Carroll, B. L. Powell, et al. High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study J. Clin. Oncol., August 1, 2007; 25(22): 3337 - 3343. [Abstract] [Full Text] [PDF] H. Kiyoi, Y. Shiotsu, K. Ozeki, S. Yamaji, H. Kosugi, H. Umehara, M. Shimizu, H. Arai, K. Ishii, S. Akinaga, et al. A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations Clin. Cancer Res., August 1, 2007; 13(15): 4575 - 4582. [Abstract] [Full Text] [PDF] J. M. Irish, N. Anensen, R. Hovland, J. Skavland, A.-L. Borresen-Dale, O. Bruserud, G. P. Nolan, and B. T. Gjertsen Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53 Blood, March 15, 2007; 109(6): 2589 - 2596. [Abstract] [Full Text] [PDF] M. Bornhauser, T. Illmer, M. Schaich, S. Soucek, G. Ehninger, C. Thiede, and for the AML SHG 96 study group Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML Blood, March 1, 2007; 109(5): 2264 - 2265. [Full Text] [PDF] R. E. Gale, R. Hills, K. Wheatley, A. K. Burnett, and D. C. Linch Response: Still a need for more robust evidence that FLT3/ITD status should influence the decision to proceed to transplantation in AML patients Blood, March 1, 2007; 109(5): 2265 - 2265. [Full Text] [PDF] A. G. Smith, L. J. Worrillow, and J. M. Allan A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia Blood, February 1, 2007; 109(3): 1233 - 1236. [Abstract] [Full Text] [PDF] K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, January 15, 2007; 109(2): 431 - 448. [Abstract] [Full Text] [PDF] H. P. Erba Prognostic Factors in Elderly Patients with AML and the Implications for Treatment Hematology, January 1, 2007; 2007(1): 420 - 428. [Abstract] [Full Text] [PDF] A. K. Burnett and S. Knapper Targeting Treatment in AML Hematology, January 1, 2007; 2007(1): 429 - 434. [Abstract] [Full Text] [PDF] S. Meshinchi, T. A. Alonzo, D. L. Stirewalt, M. Zwaan, M. Zimmerman, D. Reinhardt, G. J. L. Kaspers, N. A. Heerema, R. Gerbing, B. J. Lange, et al. Clinical implications of FLT3 mutations in pediatric AML Blood, December 1, 2006; 108(12): 3654 - 3661. [Abstract] [Full Text] [PDF] S. Meshinchi, R. J. Arceci, J. E. Sanders, F. O. Smith, W. B. Woods, J. P. Radich, T. A. Alonzo, R. E. Gale, R. Hills, K. Wheatley, et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood, July 1, 2006; 108(1): 400 - 401. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020